Britta Majchrzak-Stiller

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Locally Advanced

Basal Cell Carcinoma

Dna Damage Response

Endoplasmic Reticulum Stress

Top Venues

International journal of molecular sciences

Journal of cellular and molecular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Stephan A Hahn, Lea Skrzypczyk, Lena Beule, Waldemar Uhl, Chris Braumann, Johanna Strotmann, Philipp Höhn
Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Cancers 16 (14) (2024)
Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Stephan A Hahn, Lea Skrzypczyk, Lena Beule, Waldemar Uhl, Chris Braumann, Johanna Strotmann, Philipp Höhn
Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Cancers 16 (14) (2024)
Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Stephan A Hahn, Lea Skrzypczyk, Lena Beule, Waldemar Uhl, Chris Braumann, Johanna Strotmann, Philipp Höhn
Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Cancers 16 (14) (2024)
Thilo Gambichler, Friederike Harnischfeger, Marina Skrygan, Britta Majchrzak-Stiller, Marie Buchholz, Thomas Müller, Chris Braumann
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes. International journal of molecular sciences 24 (20) (2023)
Britta Majchrzak-Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler
GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells. Journal of cellular and molecular medicine (2023)
Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study. International journal of molecular sciences 23 (13) (2022)
Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller, Stephan A Hahn, Ilka Peters, Julian Horn, Thomas Müller, Philipp Höhn, Waldemar Uhl, Chris Braumann
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. Cancers 14 (11) (2022)